UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
Correlation between local 18F-fluorodeoxyglucose PET/CT and<br />
T-cell exhaustion for predicting treatment response in patients with<br />
advanced melanoma treated with checkpoint inhibitor mono-therapy.<br />
Authors*: Miguel Hernandez Pampaloni, Lorenzo Nardo, Alain Patrick Algazi, Katy K. Tsai, Kimberly<br />
Loo, Luca Facchetti, Susana Ortiz-Urda, Adil Daud<br />
Abstract #: 11572<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board # 269<br />
Poster Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11572)<br />
Daud Research Interests: Our group at <strong>UCSF</strong> is focused on developing new immunotherapy agents and<br />
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-<br />
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this<br />
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination<br />
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development<br />
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at<br />
<strong>UCSF</strong>, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can<br />
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets<br />
of melanoma (and potentially other cancers).<br />
http://cancer.ucsf.edu/people/profiles/daud_adil.3622<br />
__________________________________________________________________________<br />
CHK1 inhibition as a therapeutic approach in KRAS mutated and<br />
squamous cell carcinoma NSCLC patients.<br />
Authors*: Daniela Morales-Espinosa, Silvia García-Román, Miguel Angel Molina-Vila, Ana Gimenez Capitan,<br />
Jordi Bertran-Alamillo, Pedro Mendez, Santiago Viteri Ramirez, Niki Karachaliou, Rafael Rosell<br />
Abstract #: 11581<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #278<br />
Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11581)<br />
*<strong>UCSF</strong> authors in bold<br />
82
Change language